亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Benign metastasizing leiomyoma (BML): A retrospective case series analysis of 8 patients (pts).

医学 子宫切除术 转移瘤切除术 外科 相伴的 曲普瑞林 平滑肌瘤 内科学 转移 癌症 激素 促黄体激素 促性腺激素释放激素
作者
Vittoria Colia,Angelo Paolo Dei Tos,Elena Fumagalli,Rossella Bertulli,Domenica Lorusso,Francesco Raspagliesi,Carlo Morosi,Maria Luisa Carcangiu,Paolo G. Casali,Roberta Sanfilippo
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:35 (15_suppl): e22525-e22525 被引量:2
标识
DOI:10.1200/jco.2017.35.15_suppl.e22525
摘要

e22525 Background: BML is a rare entity marked by the presence of lung lesions in women with a history of surgery for a benign leiomyoma of the uterus. Optimal treatment strategy for BML is poorly defined. We report on the activity of systemic therapy in a retrospective series of pts with BML. Methods: Cases diagnosed with BML from June 1993 to January 2017 at Istituto Nazionale Tumori, Milan, were reviewed. Results: Eight pts were identified, with a median age of 43 yrs. Estrogen and progesteron receptors were positive in all cases. All pts underwent surgery (3 hysterectomy, 2 myomectomy, 2 hysteroannessiectomy and 1 left ovariectomy) for suspected uterine leiomyoma (1 leg; 1 thigh); 2 pts had concomitant lung disease. 8 pts developed lung metastases and 2 had also limb metastases. 2 pts underwent lung metastasectomy, followed by watchful waiting with CT every 6 mos and were disease-free at their last follow up after 132 mos and 84 mos from diagnosis. 6 pts received systemic therapy for progressing advanced disease (1-6 lines). Among 6 pts treated, 2 were in fertility age and underwent ovary-sparing hysterectomy, receiving GnRH agonist with 1 PR lasting 96 mos and 1 SD lasting 38 mos; 2 pts received an aromatase inhibitor with 1 PR lasting 24 mos and 1 SD lasting 12 mos; 2 pts received oral estrogens with 1 PR lasting 39 mos and 1 SD lasting 2 mos; 1 pt received oral progestins with a PR lasting 12 mos; 3 patients received antracyclin +/- ifosfamide obtaining 2 PR after 3 cycles (cys) and 1 SD after 3 cys lasting 6 mos; 1 pt received high-dose ifosfamide with a PR after 5 cys; 1 pt received ifosfamide+dacarbazine obtaining a CR after 6 cys; 2 pts received gemcitabine with 1 PR after 3 cys and 1 SD after 2 cys lasting 6 mos; 1 pt received oral etoposide with a PR lasting 21 mos; 1 pt received sorafenib with a SD lasting 6 mos; 1 pt received everolimus with a PR lasting 57 mos. In this case, everolimus was discontinued due to lung toxicity. No pts progressed during treatment. At a median follow-up of 55 mos, 6 pts are alive, while 2 are dead of disease. Conclusions: In a series of 8 pts, we confirm the activity of hormonal treatment in BML. mTOR inihibitors or chemotherapy also show to be active.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Venus完成签到 ,获得积分10
56秒前
在水一方应助chenyuns采纳,获得30
1分钟前
JACk完成签到 ,获得积分10
1分钟前
1分钟前
chenyuns发布了新的文献求助30
1分钟前
爱静静应助李伟采纳,获得10
1分钟前
1分钟前
zhangyimg发布了新的文献求助10
1分钟前
2分钟前
郜南烟发布了新的文献求助10
2分钟前
斯文败类应助郜南烟采纳,获得10
2分钟前
思源应助chenyuns采纳,获得20
2分钟前
Akim应助chenyuns采纳,获得20
3分钟前
领导范儿应助圆圆的波仔采纳,获得10
3分钟前
4分钟前
4分钟前
李爱国应助怕孤单的灵寒采纳,获得10
4分钟前
圆圆的波仔完成签到,获得积分10
4分钟前
4分钟前
4分钟前
怕孤单的灵寒完成签到,获得积分20
4分钟前
4分钟前
chenyuns发布了新的文献求助20
5分钟前
5分钟前
CZLhaust发布了新的文献求助10
5分钟前
5分钟前
Sherling发布了新的文献求助10
5分钟前
李爱国应助Sherling采纳,获得10
5分钟前
CZLhaust完成签到,获得积分10
5分钟前
5分钟前
jingjili发布了新的文献求助30
6分钟前
酷波er应助科研通管家采纳,获得10
6分钟前
6分钟前
郜南烟发布了新的文献求助10
6分钟前
6分钟前
chenyuns发布了新的文献求助20
6分钟前
科目三应助郜南烟采纳,获得10
7分钟前
anthea完成签到 ,获得积分10
7分钟前
方琼燕完成签到 ,获得积分10
7分钟前
852应助郜南烟采纳,获得10
7分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
叶剑英与华南分局档案史料 500
Foreign Policy of the French Second Empire: A Bibliography 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146771
求助须知:如何正确求助?哪些是违规求助? 2798063
关于积分的说明 7826621
捐赠科研通 2454573
什么是DOI,文献DOI怎么找? 1306394
科研通“疑难数据库(出版商)”最低求助积分说明 627708
版权声明 601527